Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1162265 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1FPR2KMT2AMEN1 | |
| SCHEMBL31378064 | 0.84 | ENPEP (0.36) | ALDH1A1L3MBTL1ENPEP | |
| SCHEMBL16975025 | 0.81 | TP53 (0.35) | ALDH1A1FPR2 | |
| SCHEMBL16975026 | 0.81 | TP53 (0.35) | ALDH1A1FPR2 | |
| SCHEMBL30579069 | 0.76 | POLB (0.32) | ALDH1A1 | |
| SCHEMBL15847361 | 0.76 | POLB (0.32) | ALDH1A1 | |
| SCHEMBL29226187 | 0.76 | POLB (0.32) | ALDH1A1 | |
| SCHEMBL866892 | 0.72 | — | — | |
| SCHEMBL12487823 | 0.72 | — | — | |
| SCHEMBL866893 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3898651-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020132658-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-9580467-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | E. R. SQUIBB & SONS, L.L.C. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160060294-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | E. R. SQUIBB & SONS, L.L.C. | 2016-03-03 | — | — | US | disclosed |
| US-9226974-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | E. R. SQUIBB & SONS, L.L.C. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140323690-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | E. R. SQUIBB & SONS, L.L.C. | 2014-10-30 | — | — | US | disclosed |
| EP-2461830-B1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8802632-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, L.L.C. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8772543-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, L.L.C. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772542-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, L.L.C. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130204033-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130197259-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130189256-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8394922-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| CN-102725001-A | Antiproliferative compounds, conjugates thereof, methods thereof, and uses thereof | MEDAREX INC | 2012-10-10 | — | — | CN | disclosed |
| EP-2461830-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | Medarex, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011017249-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20110027274-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060294-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | ALDH1A1 1030/4885L3MBTL1 95/4885FPR2 2752/4885 |
| US-20110027274-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | ALDH1A1 1030/4885L3MBTL1 95/4885FPR2 2752/4885 |
| US-20130189256-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | ALDH1A1 1030/4885L3MBTL1 95/4885FPR2 2752/4885 |
| US-20140323690-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | ALDH1A1 1030/4885L3MBTL1 95/4885FPR2 2752/4885 |
| US-20130197259-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | ALDH1A1 1030/4885L3MBTL1 95/4885FPR2 2752/4885 |
| US-20130204033-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | ALDH1A1 1030/4885L3MBTL1 95/4885FPR2 2752/4885 |
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | SDCBP, TEK, TEKT1 | ALDH1A1 4687/4885L3MBTL1 3192/4885FPR2 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.